Nestlé Health Science inks new agreement for multi-ingredient dietary supplements

Agreement includes an initial Niagen ingredient purchase commitment of $1.975 million in 2022

ChromaDex Corp., a global bioscience company dedicated to healthy ageing, has announced a new long term commercial license and supply agreement with Nestlé Health Science. The new agreement expands the previous supply agreement executed in 2018 to include dietary supplements.

The agreement provides Nestlé Health Science the non-exclusive right to manufacture, market, distribute, and sell products using nicotinamide riboside or NR, trademarked Niagen, under its brands worldwide, except where ChromaDex has existing exclusive distribution agreements.

Approved product categories include medical nutritional, functional food and beverage, and multi-ingredient dietary supplements. Consideration for the rights granted to Nestlé Health Science under the agreement include a $1.975 million initial purchase of Niagen. ChromaDex will also receive certain future commercial milestone payments upon achievement of certain net sales targets and tiered royalties relating to net sales.

ChromaDex’s proprietary ingredient, Niagen, is sold directly to consumers as Tru Niagen, which is backed by clinical and scientific research,

Read Previous

Givaudan provides view of future technologies for alternative proteins

Read Next

Korea strengthens personalised nutrition services

Leave a Reply